Human Metapneumovirus Therapeutics Market to Reach $0.93B by 2030 at 6% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Human Metapneumovirus (hMPV) Therapeutics Market Between 2026 And 2030?
The human metapneumovirus (hmpv) therapeutics market size has exhibited robust growth in recent years. It is anticipated to expand from $0.7 billion in 2025 to $0.74 billion by 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The past growth can be ascribed to the prevalent occurrence of respiratory viral infections, the scarcity of specific approved antiviral therapies for hmpv, the dependence on supportive and symptomatic treatment methods, a rise in hospitalizations among infants and elderly patients, and heightened awareness of viral lower respiratory tract infections.
The human metapneumovirus (hmpv) therapeutics market size is projected for substantial expansion in the coming years. This market is anticipated to reach $0.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. The increase during this period can be attributed to an escalating focus on developing virus-specific treatments, increased investment in respiratory virus research, a growing demand for effective therapies among immunocompromised populations, the proliferation of clinical trials for novel antiviral agents, and enhanced preparedness for seasonal respiratory virus outbreaks. Furthermore, key trends in the forecast period encompass a greater concentration on targeted antiviral therapies for respiratory viruses, a rising requirement for symptom-focused management in pediatric and geriatric patients, heightened importance placed on early intervention for high-risk populations, the broader availability of supportive care therapeutics for viral respiratory infections, and intensified clinical investigation into innovative hmpv treatment options.
Access Your Free Sample Report For In-Depth Market Analysis:
What Factors Are Contributing To The Growth Of The Human Metapneumovirus (hMPV) Therapeutics Market?
A growing incidence of respiratory infections is anticipated to propel the expansion of the human metapneumovirus (HMPV) therapeutics market moving forward. These infections represent conditions that impact the respiratory tract, encompassing the nose, throat, airways, and lungs. The escalation in respiratory infections can be attributed to increasing air pollution levels. Pollutants such as particulate matter and nitrogen dioxide irritate and weaken the respiratory tract, making individuals more susceptible to infections. Human metapneumovirus (hMPV) therapeutics are vital for managing respiratory infections caused by hMPV, working by diminishing viral replication and inflammation through antiviral treatments and supportive care, thereby enhancing health outcomes for vulnerable populations like infants, the elderly, and immunocompromised patients. For instance, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that Australia Chronic Obstructive Pulmonary Disease (COPD) accounted for 3.6% of the total disease burden in 2023. It was responsible for 50% of the overall burden from respiratory conditions, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Consequently, the rising prevalence of respiratory infections acts as a significant driver for growth in the human metapneumovirus (HMPV) therapeutics market.
How Is The Human Metapneumovirus (hMPV) Therapeutics Market Organized By Segment Classification?
The human metapneumovirus (hmpv) therapeutics market covered in this report is segmented –
1) By Drug Class: Antipyretic, Decongestants, Cough Suppressants, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-Use: Hospitals And Clinics, Academic And Research Institutions, Other End-Uses
Subsegments:
1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)
2) By Decongestants: Nasal Decongestants, Oral Decongestants
3) By Cough Suppressants: Dextromethorphan, Benzonatate
4) By Other Drug Classes: Antiviral Agents, Inhaled Corticosteroids
What Trends Are Shaping The Future Of The Human Metapneumovirus (hMPV) Therapeutics Market?
Key players in the human metapneumovirus (hMPV) therapeutics market are concentrating on creating precise antiviral treatments, including monoclonal antibodies, for the effective management of hMPV infections. Monoclonal antibodies (mAbs) are synthetically produced proteins designed to emulate the immune system’s inherent capacity to combat illnesses. These antibodies offer focused treatment for a range of conditions, such as cancer and autoimmune disorders, by selectively attaching to and rendering inert detrimental antigens or cells. As an illustration, in October 2024, Vicebio Ltd., a biopharmaceutical firm based in the UK, successfully obtained $100 million through Series B financing, spearheaded by TCGX with contributions from Goldman Sachs Alternatives and other investors, intended to propel the development of its advanced respiratory virus vaccines. This investment will facilitate the Phase 1 clinical trial for VXB-241, a bivalent vaccine designed to target RSV and hMPV, with preliminary findings anticipated in mid-2025. Furthermore, it will expedite the creation of VXB-251, a trivalent vaccine aiming at RSV, hMPV, and Parainfluenza Virus 3, with the goal of alleviating substantial health challenges faced by older individuals.
Who Are The Industry Participants Involved In The Human Metapneumovirus (hMPV) Therapeutics Market?
Major companies operating in the human metapneumovirus (hmpv) therapeutics market are Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc.
Get The Full Human Metapneumovirus (hMPV) Therapeutics Market Report:
Which Region Represents The Largest Share Of The Human Metapneumovirus (hMPV) Therapeutics Market?
North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus (hmpv) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Human Metapneumovirus (hMPV) Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Human Metapneumovirus (hMPV) Therapeutics Market 2026, By The Business Research Company
Antivirals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Viral Hepatitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
Respiratory Syncytial Virus Rsv Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
